Liver Cancer Fusion Predictor
A molecular blood test evaluating cancer-associated fusion-transcript signals associated with HCC.
What makes it different?
Cancer-associated fusion transcripts are RNA signals linked to certain genomic rearrangements. Their investigation provides a distinct molecular perspective on HCC biology. The Liver Cancer Fusion Predictor applies a proprietary multi-marker approach whose full assay composition and interpretation rules are not publicly disclosed.
How the technology works
Molecular methods enable analysis of selected circulating fusion-transcript signals, which inform a proprietary computational approach. Fusion-detect™ denotes MoleculeDx’s underlying fusion-transcript technology; Liver Cancer Fusion Predictor denotes the HCC screening test. The public description is not an exhaustive list of assay inputs.
Research evidence
Published work has evaluated serum fusion transcripts and predictive models in HCC and non-HCC cohorts. Published performance measures are study-specific; they should not be assumed to describe every commercial use of the test.
Pricing and ordering
The current standard package shown in the booking portal is $160. Collection options, service areas, and final terms are confirmed during the booking process.
Ready to learn more?
Discuss appropriate HCC surveillance with your healthcare professional. Start an order through the secure MoleculeDx booking portal.